Nephrocare Health Services Peer Comparison
NSE: NEPHROPLUS | BSE: 544647
₹616.40
As on 09-Oct-2026IST
Market cap
₹6,188 Cr
Revenue (TTM)
₹999 Cr
P/E Ratio
80.5
P/B Ratio
5.5
Div. Yield
0 %
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
6,188 | 35,327 | 32,438 | 29,602 | 16,591 |
Revenue (₹ Cr) |
999 | 4,683 | 2,891 | 4,213 | 1,446 |
Net Profit (₹ Cr) |
76.84 | 552.34 | 546.30 | 190.80 | 164.14 |
Net Margin (%) |
7.51 | 11.55 | 18.23 | 4.49 | 11.28 |
RoE (%) |
9.22 | 14.93 | 23.03 | 9.45 | 15.36 |
Price to Earnings |
80.53 | 63.52 | 59.86 | 144.90 | 99.59 |
Price-To-Book |
5.46 | 8.59 | 12.41 | 7.82 | 11.67 |
Income Statement (₹ Cr)
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Operating Revenue
|
998.85 | 4,410.27 | 2,762.91 | 3,904.60 | 1,445.69 |
|
Total Income
|
1,023.36 | 4,514.67 | 2,864.18 | 3,930.80 | 1,455.17 |
|
Total Expenditure
|
771.88 | 3,486.05 | 1,980.40 | 3,090.00 | 1,124.24 |
|
EBITDA
|
226.96 | 924.22 | 782.52 | 814.60 | 321.44 |
|
Depreciation
|
90.67 | 222.54 | 161.80 | 283.20 | 63.64 |
|
EBIT
|
136.30 | 701.68 | 620.71 | 531.40 | 257.80 |
|
Interest
|
60.24 | 90.05 | 22.80 | 215.10 | 33.47 |
|
Other Income
|
24.51 | 104.41 | 101.27 | 26.20 | 9.48 |
|
Exceptional Items
|
-- | -1.02 | -30.09 | -11.20 | -0.49 |
|
Profit before Tax
|
97.47 | 715.02 | 669.09 | 333.90 | 231.14 |
|
Provision for Tax
|
20.63 | 160.95 | 159.33 | 91.90 | 67.00 |
|
Profit after Tax
|
76.84 | 554.07 | 509.75 | 242.00 | 164.14 |
Liabilities (₹ Cr)
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,116.49 | 3,961.57 | 2,508.14 | 2,247.40 | 1,169.34 |
|
Minority Interest
|
-- | 22.71 | 33.14 | 311.10 | 139.44 |
|
Non-Current Liabilities
|
21.00 | 1,277.95 | 66.56 | 3,833.90 | 230.74 |
|
Current Liabilities
|
299.41 | 627.13 | 450.62 | 1,238.90 | 557.36 |
|
Total Liabilities
|
1,467.32 | 5,905.00 | 3,139.97 | 7,690.70 | 2,115.31 |
Assets (₹ Cr)
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
597.74 | 4,214.44 | 1,491.97 | 6,693.90 | 712.03 |
|
Current Assets
|
839.17 | 1,674.92 | 1,566.49 | 937.40 | 1,384.84 |
|
Total Assets
|
1,467.32 | 5,905.00 | 3,139.97 | 7,690.70 | 2,115.31 |
|
Total Debt*
|
23.02 | 631.08 | 0.00 | 3,244.00 | 412.64 |
|
Net Current Assets
|
539.76 | 1,047.79 | 1,115.88 | -301.50 | 827.48 |
|
Contingent Liabilities
|
-- | 100.01 | 16.76 | 81.10 | 168.74 |
Cashflow (₹ Cr)
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
232.58 | 714.39 | 635.61 | 510.80 | 50.39 |
|
Cash Flow from Investing Activities
|
-410.44 | -1,089.11 | -421.86 | -1,451.70 | -93.22 |
|
Cash from Financing Activities
|
157.11 | 271.85 | -263.57 | 940.30 | 276.07 |
|
Net Cash Inflow / Outflow
|
-20.75 | -102.87 | -49.83 | -0.60 | 233.23 |
Ratios
Profitability Ratios
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.18 | 19.38 | 29.56 | 11.51 | 19.79 |
|
ROE (%)
|
9.22 | 15.12 | 22.37 | 11.04 | 15.36 |
|
ROA (%)
|
6.37 | 10.43 | 17.92 | 3.64 | 9.35 |
|
EBIT Margin (%)
|
25.18 | 23.32 | 31.99 | 21.53 | 22.89 |
|
Net Margin (%)
|
7.51 | 12.27 | 17.80 | 6.16 | 11.28 |
|
Cash Profit Margin (%)
|
16.77 | 17.61 | 24.31 | 13.45 | 15.76 |
Growth Ratios
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.16 | 19.44 | 12.25 | 28.65 | 41.68 |
|
EBIT Growth (%)
|
39.14 | 6.57 | 12.01 | 1.93 | 22.68 |
|
Net Profit Growth (%)
|
14.52 | 15.11 | 3.56 | -41.66 | 18.45 |
|
EPS Growth (%)
|
-89.93 | 15.54 | 3.39 | -37.22 | 14.85 |
|
Book Value Growth (%)
|
93.44 | 16.51 | 15.41 | 5.13 | 20.75 |
Valuation Ratios
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Price / Earnings
|
66.02 | 46.44 | 43.61 | 103.16 | 0.00 |
|
Price / Book Value
|
4.62 | 6.55 | 9.01 | 11.08 | 0.00 |
|
Dividend Yield (%)
|
0.00 | 0.05 | 1.56 | 0.00 | -- |
|
EV/EBITDA
|
19.25 | 24.64 | 23.88 | 33.39 | 0.17 |
|
Market Cap (₹ Cr)
|
5,072.73 | 25,841.07 | 22,015.15 | 24,901.98 | 0.00 |
Solvency Ratios
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.02 | 0.16 | 0.00 | 1.44 | 0.35 |
|
Short term debt to equity ratio
|
0.01 | -- | -- | 0.15 | 0.15 |
|
Current Ratio
|
2.80 | 2.67 | 3.48 | 0.76 | 2.48 |
|
Quick Ratio
|
2.69 | 2.54 | 3.38 | 0.68 | 1.68 |
|
Interest Coverage
|
2.62 | 8.94 | 30.35 | 2.55 | 7.91 |
Operating Efficiency Ratios
| Nephrocare Health Services | Global Health | Dr. Lal Pathlabs | Krishna Institute | Molbio Diagnostics | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
31.73 | 9.32 | 4.01 | 14.19 | 28.27 |
|
Asset Turnover
|
0.83 | 0.83 | 0.97 | 0.59 | 0.82 |
|
Receivable days
|
106.58 | 29.09 | 13.13 | 44.38 | 85.89 |
|
Inventory Days
|
10.90 | 6.05 | 5.28 | 7.52 | 111.74 |
|
Payable days
|
205.92 | 80.04 | 118.67 | 133.54 | 136.11 |
|
Cash Conversion Cycle
|
-88.44 | -44.90 | -100.26 | -81.64 | 61.52 |